New antibody shot shows promise against malaria in early trial

NCT ID NCT05891236

Completed Disease control Sponsor: Gates Medical Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a lab-made antibody called MAM01 in 63 healthy adults who had never had malaria. The goal was to see if it is safe and can prevent malaria infection when people are deliberately exposed to the parasite. The study is complete, but results are not yet public.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MAM01 (a lab-made antibody that targets the malaria parasite)
What this could lead to: If successful, this antibody could provide temporary protection against malaria, especially for travelers or in outbreaks.
What could go wrong: This is a very early, small trial (63 people) in healthy adults who have never had malaria. It may not work in real-world settings or provide long-term protection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malaria prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALARIA

Contacts and locations

Locations

Center for Vaccine Development and Global Health, 685 W. Baltimore Street

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.